The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment
暂无分享,去创建一个
[1] Stephannie L. Furtak,et al. Magnetic resonance spectroscopy study of the glutamatergic system in adolescent males with high-functioning autistic disorder: a pilot study at 4T , 2013, European Archives of Psychiatry and Clinical Neuroscience.
[2] J. Stockman,et al. Prevalence of Parent-Reported Diagnosis of Autism Spectrum Disorder Among Children in the US, 2007 , 2011 .
[3] Donald C. Rojas,et al. Decreased left perisylvian GABA concentration in children with autism and unaffected siblings , 2014, NeuroImage.
[4] E. Bacchelli,et al. Screening of nine candidate genes for autism on chromosome 2q reveals rare nonsynonymous variants in the cAMP-GEFII gene , 2003, Molecular Psychiatry.
[5] M. Spence,et al. A case of autism with an interstitial deletion on 4q leading to hemizygosity for genes encoding for glutamine and glycine neurotransmitter receptor sub-units (AMPA 2, GLRA3, GLRB) and neuropeptide receptors NPY1R, NPY5R , 2004, BMC Medical Genetics.
[6] Laurent Mottron,et al. NLGN3/NLGN4 gene mutations are not responsible for autism in the Quebec population , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[7] Stephen J. Guter,et al. A genomewide screen for autism: strong evidence for linkage to chromosomes 2q, 7q, and 16p. , 2001, American journal of human genetics.
[8] A. Toga,et al. Elevated Glutamatergic Compounds in Pregenual Anterior Cingulate in Pediatric Autism Spectrum Disorder Demonstrated by 1H MRS and 1H MRSI , 2012, PloS one.
[9] Stephen J. Guter,et al. AProspective, Open-Label Trial of Memantine in the Treatment of Cognitive, Behavioral, and Memory Dysfunction in Pervasive Developmental Disorders , 2006 .
[10] M. Tranfaglia,et al. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP , 2005, Neuropharmacology.
[11] K. Hashimoto. Emerging role of glutamate in the pathophysiology of major depressive disorder , 2009, Brain Research Reviews.
[12] J. Mann,et al. PET and SPECT tracers for glutamate receptors. , 2013, Drug discovery today.
[13] Fred H. Gage,et al. Altered synaptic physiology and reduced susceptibility to kainate-induced seizures in GluR6-deficient mice , 1998, Nature.
[14] M. Cuccaro,et al. Autism and epilepsy: Historical perspective , 2010, Brain and Development.
[15] J. Miles. Autism spectrum disorders—A genetics review , 2011, Genetics in Medicine.
[16] T. Hassan,et al. Blood and Brain Glutamate Levels in Children with Autistic Disorder. , 2013 .
[17] Kenji Mori,et al. Non-Invasive Evaluation of the GABAergic/Glutamatergic System in Autistic Patients Observed by MEGA-Editing Proton MR Spectroscopy Using a Clinical 3 Tesla Instrument , 2011, Journal of autism and developmental disorders.
[18] B. Leventhal,et al. Family-based association testing of glutamate transporter genes in autism. , 2011, Psychiatric genetics.
[19] S. Musumeci,et al. Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediated signalling in disorders associated with Intellectual Disability and Autism , 2014, Neuroscience & Biobehavioral Reviews.
[20] Yi Zhang,et al. Sibling recurrence and the genetic epidemiology of autism. , 2010, The American journal of psychiatry.
[21] S. Whiteside,et al. A magnetic resonance spectroscopy investigation of obsessive–compulsive disorder and anxiety , 2006, Psychiatry Research: Neuroimaging.
[22] Christine DeLorenzo,et al. in vivo Variation in Metabotropic Glutamate Receptor Subtype 5 Binding Using Positron Emission Tomography and [11C]ABP688 , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[23] R. Gur,et al. GABAB-mediated rescue of altered excitatory–inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction , 2012, Translational Psychiatry.
[24] Tanya M. Teslovich,et al. A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism. , 2008, American journal of human genetics.
[25] E. Martin,et al. In vivo detection of GABA and glutamate with MEGA‐PRESS: Reproducibility and gender effects , 2011, Journal of magnetic resonance imaging : JMRI.
[26] Zhen Yan,et al. Shank3 Deficiency Induces NMDA Receptor Hypofunction via an Actin-Dependent Mechanism , 2013, The Journal of Neuroscience.
[27] Gregor Hasler,et al. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. , 2007, Archives of general psychiatry.
[28] N. W. Pedigo,et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. , 2002, Alcoholism, clinical and experimental research.
[29] Talakad G. Lohith,et al. Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome? , 2013, Molecular Autism.
[30] P. Hagerman. The fragile X prevalence paradox , 2008, Journal of Medical Genetics.
[31] C. Skinner,et al. Neurexin 1α structural variants associated with autism , 2008, Neuroscience Letters.
[32] Thomas Bourgeron,et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism , 2003, Nature Genetics.
[33] D. Licatalosi,et al. FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism , 2011, Cell.
[34] G. Barker,et al. Reduced subcortical glutamate/glutamine in adults with autism spectrum disorders: a [1H]MRS study , 2013, Translational Psychiatry.
[35] Z. Talebizadeh,et al. Novel splice isoforms for NLGN3 and NLGN4 with possible implications in autism , 2005, Journal of Medical Genetics.
[36] Q. Guan,et al. The Two Different Effects of the Potential Neuroprotective Compound Minocycline on AMPA-Type Glutamate Receptors , 2012, Pharmacology.
[37] Silvia Bernardi,et al. In vivo 1H-magnetic resonance spectroscopy study of the attentional networks in autism , 2011, Brain Research.
[38] D. Gutmann,et al. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex , 2008, Annals of neurology.
[39] G. Carlson. Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders , 2012, Pharmacology Biochemistry and Behavior.
[40] Luke Bloy,et al. GABA estimation in the brains of children on the autism spectrum: Measurement precision and regional cortical variation , 2014, NeuroImage.
[41] S. Baron-Cohen,et al. Task-related functional connectivity in autism spectrum conditions: an EEG study using wavelet transform coherence , 2013, Molecular Autism.
[42] R C Elston,et al. Linkage and association to genetic markers. , 1995, Experimental and clinical immunogenetics.
[43] M. Bear,et al. STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study , 2014, Journal of autism and developmental disorders.
[44] Eileen Daly,et al. In vivo 1H-magnetic resonance spectroscopy study of amygdala-hippocampal and parietal regions in autism. , 2006, The American journal of psychiatry.
[45] Dick J. Drost,et al. Evidence for Cortical Dysfunction in Autism: A Proton Magnetic Resonance Spectroscopic Imaging Study , 2007, Biological Psychiatry.
[46] David B. Holiday,et al. Seizures in fragile X syndrome: characteristics and comorbid diagnoses. , 2010, American journal on intellectual and developmental disabilities.
[47] R. Hagerman,et al. TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME. , 2012, Research in autism spectrum disorders.
[48] D. Pinto,et al. Rare deletions at the neurexin 3 locus in autism spectrum disorder. , 2012, American journal of human genetics.
[49] Mark F. Bear,et al. Correction of Fragile X Syndrome in Mice , 2007, Neuron.
[50] B. Christie,et al. NMDA receptor hypofunction in the dentate gyrus and impaired context discrimination in adult Fmr1 knockout mice , 2012, Hippocampus.
[51] C. McDougle,et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome , 2013, Psychopharmacology.
[52] Adam G. Carter,et al. GABAB receptor modulation of synaptic function , 2011, Current Opinion in Neurobiology.
[53] A. Kolevzon,et al. Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency , 2013, Molecular Autism.
[54] Mira Park,et al. Family based association of GRIN2A and GRIN2B with Korean autism spectrum disorders , 2012, Neuroscience Letters.
[55] N. Rinehart,et al. Autism and ADHD: How far have we come in the comorbidity debate? , 2011, Neuroscience & Biobehavioral Reviews.
[56] Henry Markram,et al. Elevated NMDA receptor levels and enhanced postsynaptic long-term potentiation induced by prenatal exposure to valproic acid , 2007, Proceedings of the National Academy of Sciences.
[57] J. Storm-Mathisen,et al. Down‐regulation of Glial Glutamate Transporters after Glutamatergic Denervation in the Rat Brain , 1995, The European journal of neuroscience.
[58] D. Geschwind,et al. Autism spectrum disorders: developmental disconnection syndromes , 2007, Current Opinion in Neurobiology.
[59] T. Struffert,et al. Multi-voxel magnetic resonance spectroscopy at 3T in patients with idiopathic generalised epilepsy , 2010, Seizure.
[60] T. Bourgeron,et al. Linkage and association of the glutamate receptor 6 gene with autism , 2002, Molecular Psychiatry.
[61] K. Phan,et al. Anterior cingulate neurochemistry in social anxiety disorder: 1H-MRS at 4 Tesla , 2005, Neuroreport.
[62] M. Mizuguchi,et al. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex , 2012, Nature Communications.
[63] K. Strauch,et al. No evidence for involvement of genetic variants in the X‐linked neuroligin genes NLGN3 and NLGN4X in probands with autism spectrum disorder on high functioning level , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[64] J. Buxbaum,et al. Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay , 2013, Molecular Autism.
[65] Albert David,et al. X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. , 2004, American journal of human genetics.
[66] L. DeLisi,et al. Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia , 2011, Translational Psychiatry.
[67] Lisa Blaskey,et al. MEG detection of delayed auditory evoked responses in autism spectrum disorders: towards an imaging biomarker for autism , 2010, Autism research : official journal of the International Society for Autism Research.
[68] L. Soorya,et al. Metabolic mapping of deep brain structures and associations with symptomatology in autism spectrum disorders. , 2014, Research in autism spectrum disorders.
[69] Christian R Marshall,et al. Contribution of SHANK3 mutations to autism spectrum disorder. , 2007, American journal of human genetics.
[70] M. Carlsson,et al. Hypothesis: Is infantile autism a hypoglutamatergic disorder? Relevance of glutamate – serotonin interactions for pharmacotherapy , 1998, Journal of Neural Transmission.
[71] Peter Teale,et al. BMC Psychiatry BioMed Central Research article Use of antipsychotics and benzodiazepines in patients with psychiatric emergencies: Results of an observational trial , 2008 .
[72] P. Hagerman,et al. Autism profiles of males with fragile X syndrome. , 2008, American journal of mental retardation : AJMR.
[73] K. J. Parker,et al. Distinct Plasma Profile of Polar Neutral Amino Acids, Leucine, and Glutamate in Children with Autism Spectrum Disorders , 2011, Journal of Autism and Developmental Disorders.
[74] Mark F. Bear,et al. Altered synaptic plasticity in a mouse model of fragile X mental retardation , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[75] G. Blatt,et al. Decreased GAD67 mRNA levels in cerebellar Purkinje cells in autism: pathophysiological implications , 2007, Acta Neuropathologica.
[76] M. Bear,et al. Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice , 2012, Neuron.
[77] M. Bear,et al. Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial , 2012, Science Translational Medicine.
[78] S. Spence,et al. A genomewide screen of 345 families for autism-susceptibility loci. , 2003, American journal of human genetics.
[79] B. Christie,et al. Rescue of NMDAR-dependent synaptic plasticity in Fmr1 knock-out mice. , 2015, Cerebral cortex.
[80] Stephen J. Guter,et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. , 2006, Journal of child and adolescent psychopharmacology.
[81] C. McDougle,et al. An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. , 2011, Journal of child and adolescent psychopharmacology.
[82] M. Mohammadi,et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. , 2013, The international journal of neuropsychopharmacology.
[83] Chao Lu,et al. Retrospective study , 2016, Medicine.
[84] Geraldine Dawson,et al. Atypical developmental patterns of brain chemistry in children with autism spectrum disorder. , 2013, JAMA psychiatry.
[85] D. Rojas,et al. Increased Glutamate Concentration in the Auditory Cortex of Persons With Autism and First‐Degree Relatives: A 1H‐MRS Study , 2013, Autism research : official journal of the International Society for Autism Research.
[86] A. Fisahn,et al. Kainate receptors and rhythmic activity in neuronal networks: hippocampal gamma oscillations as a tool , 2005, The Journal of physiology.
[87] T. Kemper,et al. Density and Distribution of Hippocampal Neurotransmitter Receptors in Autism: An Autoradiographic Study , 2001, Journal of autism and developmental disorders.
[88] T. Südhof,et al. Neuroligin-1 Deletion Results in Impaired Spatial Memory and Increased Repetitive Behavior , 2010, The Journal of Neuroscience.
[89] P. Conn,et al. Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.
[90] S. Bryson,et al. Recurrence Risk for Autism Spectrum Disorders: A Baby Siblings Research Consortium Study , 2011, Pediatrics.
[91] Yiping Shen,et al. Deletions of NRXN1 (Neurexin-1) Predispose to a Wide Spectrum of Developmental Disorders , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[92] M. Sheng. The postsynaptic NMDA-receptor--PSD-95 signaling complex in excitatory synapses of the brain. , 2001, Journal of cell science.
[93] B. Cormand,et al. Rare variants analysis of neurexin-1&bgr; in autism reveals a novel start codon mutation affecting protein levels at synapses , 2013, Psychiatric genetics.
[94] A. Ghanizadeh. Increased Glutamate and Homocysteine and Decreased Glutamine Levels in Autism: A Review and Strategies for Future Studies of Amino Acids in Autism , 2013, Disease markers.
[95] S. Rogers,et al. The Behavioral Phenotype in Fragile X: Symptoms of Autism in Very Young Children with Fragile X Syndrome, Idiopathic Autism, and Other Developmental Disorders , 2001, Journal of developmental and behavioral pediatrics : JDBP.
[96] C. McDougle,et al. Open-Label Memantine in Fragile X Syndrome , 2009, Journal of autism and developmental disorders.
[97] H. McDermid,et al. The 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome) , 2011, Molecular Syndromology.
[98] D. Ethell,et al. Open-label add-on treatment trial of minocycline in fragile X syndrome , 2010, BMC neurology.
[99] A. Bailey,et al. Autism as a strongly genetic disorder: evidence from a British twin study , 1995, Psychological Medicine.
[100] Hongyan Wang,et al. Lack of Association between NLGN3, NLGN4, SHANK2 and SHANK3 Gene Variants and Autism Spectrum Disorder in a Chinese Population , 2013, PloS one.
[101] J. Brunso-Bechtold,et al. Differential effects of aging and insulin-like growth factor-1 on synapses in CA1 of rat hippocampus. , 2005, Cerebral cortex.
[102] M. Reiff. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. , 2001 .
[103] L. Schieve,et al. Prevalence of Parent-Reported Diagnosis of Autism Spectrum Disorder Among Children in the US, 2007 , 2009, Pediatrics.
[104] Yosuke Kameno,et al. Alteration of Plasma Glutamate and Glutamine Levels in Children with High-Functioning Autism , 2011, PloS one.
[105] D. Nguyen,et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome , 2009, Journal of Medical Genetics.
[106] Yoshio Minabe,et al. Increased serum levels of glutamate in adult patients with autism , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[107] P. Turnpenny,et al. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. , 2005, Developmental medicine and child neurology.
[108] J. Swann,et al. Multiple Roles for Mammalian Target of Rapamycin Signaling in Both Glutamatergic and GABAergic Synaptic Transmission , 2012, The Journal of Neuroscience.
[109] C. McDougle,et al. Brief Report: Acamprosate in Fragile X Syndrome , 2010, Journal of autism and developmental disorders.
[110] Kenny Q. Ye,et al. Strong Association of De Novo Copy Number Mutations with Autism , 2007, Science.
[111] K. McBride,et al. Genetic testing in autism: how much is enough? , 2007, Genetics in Medicine.
[112] Family‐based association for quantitative traits. , 2014 .
[113] Aberrant basal ganglia metabolism in fragile X syndrome: a magnetic resonance spectroscopy study , 2013, Journal of Neurodevelopmental Disorders.
[114] K. Hashimoto,et al. Enzymes in the glutamate-glutamine cycle in the anterior cingulate cortex in postmortem brain of subjects with autism , 2013, Molecular Autism.
[115] Jullie W Pan,et al. Rett Syndrome: 1H Spectroscopic Imaging at 4.1 Tesla , 1999, Journal of child neurology.
[116] L. Borjas,et al. Plasma excitatory amino acids in autism. , 1996, Investigacion clinica.
[117] K. Davis,et al. Linkage and association of the mitochondrial aspartate/glutamate carrier SLC25A12 gene with autism. , 2004, The American journal of psychiatry.
[118] Axel Benner,et al. Further characterization of the autism susceptibility locus AUTS1 on chromosome 7q. , 2001, Human molecular genetics.
[119] A. Williamson,et al. Overexpression of GluR6 in Rat Hippocampus Produces Seizures and Spontaneous Nonsynaptic Bursting in Vitro , 2000, Neurobiology of Disease.
[120] Dai Zhang,et al. Family‐based association study between autism and glutamate receptor 6 gene in Chinese Han trios , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[121] J. Jordán,et al. Neuroprotectant minocycline depresses glutamatergic neurotransmission and Ca2+ signalling in hippocampal neurons , 2007, The European journal of neuroscience.
[122] M. Fitzgerald,et al. Plasma Amino Acid Levels in Children with Autism and Their Families , 2003, Journal of autism and developmental disorders.
[123] Stephen T Warren,et al. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. , 2012, Annual review of pathology.
[124] C. McDougle,et al. A retrospective study of memantine in children and adolescents with pervasive developmental disorders , 2007, Psychopharmacology.
[125] Alcino J. Silva,et al. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders. , 2011, Trends in molecular medicine.
[126] M. Cuccaro,et al. Autism spectrum disorders and epilepsy: Moving towards a comprehensive approach to treatment , 2010, Brain and Development.
[127] Norbert Schuff,et al. Age-related glutamate and glutamine concentration changes in normal human brain: 1H MR spectroscopy study at 4 T , 2005, Neurobiology of Aging.
[128] P. Garcia,et al. Minocycline- and tetracycline-class antibiotics are protective against partial seizures in vivo , 2012, Epilepsy & Behavior.
[129] T. Südhof,et al. Common circuit defect of excitatory-inhibitory balance in mouse models of autism , 2009, Journal of Neurodevelopmental Disorders.
[130] James H. Eubanks,et al. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome , 2006, Neurobiology of Disease.
[131] R. Citraro,et al. New AMPA antagonists in epilepsy , 2012, Expert opinion on investigational drugs.
[132] L. Borjas,et al. [Clinical heterogeneity of the autistic syndrome: a study of 60 families]. , 1992, Investigacion clinica.
[133] Bonnie M. MacNeil,et al. Anxiety in Children and Adolescents with Autism Spectrum Disorders. , 2009 .
[134] S. Rivera,et al. A Randomized Double-Blind, Placebo-Controlled Trial of Minocycline in Children and Adolescents with Fragile X Syndrome , 2013, Journal of developmental and behavioral pediatrics : JDBP.
[135] M. Waters,et al. of Insulin-Like Growth , 1993 .
[136] M. Rutter,et al. Genetics and child psychiatry: II Empirical research findings. , 1999, Journal of child psychology and psychiatry, and allied disciplines.
[137] J. Walecki,et al. Proton Magnetic Resonance Spectroscopy Study of Brain Metabolite Changes after Antipsychotic Treatment , 2011, Pharmacopsychiatry.
[138] R. Martínez-Leal,et al. Mutations affecting synaptic levels of neurexin-1β in autism and mental retardation , 2012, Neurobiology of Disease.
[139] S. Schachter,et al. The NMDA receptor complex as a therapeutic target in epilepsy: a review , 2011, Epilepsy & Behavior.
[140] J. Edgar,et al. Validating γ Oscillations and Delayed Auditory Responses as Translational Biomarkers of Autism , 2010, Biological Psychiatry.
[141] Thomas Bourgeron,et al. Mapping autism risk loci using genetic linkage and chromosomal rearrangements , 2007, Nature Genetics.
[142] K. Grotemeyer,et al. Serotonin and amino acid content in platelets of autistic children , 1993, Acta psychiatrica Scandinavica.
[143] S. Fatemi,et al. Metabotropic Glutamate Receptor 5 Upregulation in Children with Autism is Associated with Underexpression of Both Fragile X Mental Retardation Protein and GABAA Receptor Beta 3 in Adults with Autism , 2011, Anatomical record.
[144] F. Serajee,et al. The metabotropic glutamate receptor 8 gene at 7q31: partial duplication and possible association with autism , 2003, Journal of medical genetics.
[145] Janice Branson,et al. Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056 , 2011, Science Translational Medicine.
[146] H. Niederhofer. Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism. , 2007, Journal of clinical psychopharmacology.
[147] G. Arbanas. Diagnostic and Statistical Manual of Mental Disorders (DSM-5) , 2015 .
[148] David R. Hampson,et al. Increased GABAB Receptor-Mediated Signaling Reduces the Susceptibility of Fragile X Knockout Mice to Audiogenic Seizures , 2009, Molecular Pharmacology.
[149] C. Shepherd,et al. A prevalence study of autism in tuberous sclerosis , 1993, Journal of autism and developmental disorders.
[150] S. Kennedy,et al. Novel therapeutic targets in depression: Minocycline as a candidate treatment , 2012, Behavioural Brain Research.
[151] A. Hardan,et al. Underutilization of Genetics Services for Autism: The Importance of Parental Awareness and Provider Recommendation , 2012, Journal of Genetic Counseling.
[152] Carlos A. Zarate,et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders , 2008, Nature Reviews Drug Discovery.
[153] M. Chez,et al. Memantine as Adjunctive Therapy in Children Diagnosed With Autistic Spectrum Disorders: An Observation of Initial Clinical Response and Maintenance Tolerability , 2007, Journal of child neurology.
[154] Janet E. Lainhart,et al. Overrepresentation of mood and anxiety disorders in adults with autism and their first‐degree relatives: what does it mean? , 2008, Autism research : official journal of the International Society for Autism Research.
[155] Mark F Bear,et al. The mGluR theory of fragile X mental retardation , 2004, Trends in Neurosciences.
[156] J. Pevsner,et al. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism , 2001, Neurology.
[157] J. Mowrey,et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. , 2009, American journal of human genetics.
[158] Ryszard Przewłocki,et al. Behavioral Alterations in Rats Prenatally Exposed to Valproic Acid: Animal Model of Autism , 2005, Neuropsychopharmacology.
[159] L. Lee,et al. A pilot open-label trial of minocycline in patients with autism and regressive features , 2013, Journal of Neurodevelopmental Disorders.
[160] Sheik Hosenbocus,et al. Memantine: a review of possible uses in child and adolescent psychiatry. , 2013, Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent.
[161] R. S. Jones. The NMDA receptor Edited by J. C. Watkins and G. L. Collinridge. Oxford University Press, New York (1990) 242 pp. £45.00 , 1991, Neuroscience.
[162] C. Betancur,et al. Etiological heterogeneity in autism spectrum disorders: More than 100 genetic and genomic disorders and still counting , 2011, Brain Research.
[163] D. Toncheva,et al. Analysis of the genes encoding neuroligins NLGN3 and NLGN4 in Bulgarian patients with autism. , 2012, Genetic counseling.
[164] S. Schulz,et al. Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices , 2002, Biological Psychiatry.